Traws Pharma Q1 2024 net loss $5.0M; cash $16.4M, extended by $14M April raise

Traws Pharma, Inc.

2024-Q1 EPS reported -$0.24 revenue$56,000

Cash $16.4M at March 31, 2024; raised $14M in April from TPAV/OrbiMed, funding into Q4 2024.
Net loss $5.0M ($0.24/shr) vs $5.8M ($0.28/shr) in Q1 2023; R&D down to $1.9M from $4.1M.
Completed acquisition of Trawsfynydd and concurrent $14M private placement in April 2024.
Initiated Phase 1 dosing for COVID candidate ratutrelvir; last dose cohort for narazaciclib done.
Plans Phase 2 for influenza and COVID in H2 2024; topline data expected H1 2025.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Traws Pharma, Inc. reported the first quarter of 2024 results: revenue fifty-six thousand dollars, net income $5.0 million, or $0.24 per share, EPS $0.24 per share.

Period: the first quarter of 2024
Revenue: fifty-six thousand dollars
Net income: $5.0 million, or $0.24 per share
EPS: $0.24 per share
Result: reported results

Exact text from the filing

Revenue was fifty-six thousand dollars for the first quarter of 2024, consistent with the same period in 2023.

View on SEC.gov

Browse all earnings releases →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-062544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.